|Arrowhead Research Corporation Acquires Early Nanosensor Patent Portfolio|
PASADENA, Calif.--(BUSINESS WIRE)--May 19, 2005--Arrowhead Research Corporation (NASDAQ:ARWR - News; NASDAQ:ARWRW - News) announced today that it has acquired a suite of patent and patent applications covering nanosensor technology developed by Dr. Hermann Gaub, a Professor of Biophysics at the Center for Nanoscience at Ludwig-Maximilians University in Munich. Arrowhead and its subsidiaries now own or have licenses to over 250 U.S. and international patents and patent applications.
"Nanosensors are expected to radically change the way we diagnose disease. Now, we go to the doctor's office to have large samples of blood taken and then wait for days to get the results from a remote laboratory," said R. Bruce Stewart, President of Arrowhead. "With a nanosensor-enabled device, tests could be performed with a single drop of blood - and the results obtained within minutes."
The portfolio covers techniques for measuring biomolecular interactions by single-molecule force spectroscopy. As reported in "Science" in 2003, the devices are sensitive enough to detect single-base pair mismatches of DNA and have demonstrated significant improvement over state-of-the-art instrumentation. The patent applications also cover construction of parallel assays for placing millions of sensors on a chip. These patent and patent applications were acquired for a di minimus cash payment and are complementary to other patents to which Arrowhead already has rights.